Extrapyramidal Symptoms Associated with Antipsychotic Use
|
|
- Collin Cummings
- 5 years ago
- Views:
Transcription
1 Extrapyramidal Symptoms Associated with Antipsychotic Use Tamara Pringsheim, MD, FRCPC, FAAN Associate Professor, University of Calgary Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences
2 Extrapyramidal Symptoms Preferred term now is drug-induced movement disorders Can be seen with many types of drugs Antipsychotics, dopamine-receptor blocking drugs and dopamine depleting drugs are most frequently associated with drug-induced movement disorders
3 First Generation Antipsychotics (FGAs)
4 FGAs: Chemical Classification Phenothiazines Non-phenothiazines Butyrophenones Thioxanthenes Dihydroindolones Dibenzepines Diphenylbutylpiperidines
5 Phenothiazines Share the same three-ring structure Three subclasses: Aliphatic, Piperidine, Piperazine Fluphenazine Very high D2 activity Moderate 5HT2 activity Low muscarinic activity Low alpha 1 adrenergic activity Moderate antihistamine activity
6 Non-phenothiazines Butyrophenones: Haloperidol Very high D2 activity Moderate 5HT2 activity Low muscarinic, alpha 1 adrenergic and antihistamine activity Diphenylbutylpiperidines: Pimozide Very high D2 activity Moderate 5HT2 activity Low muscarinic, alpha 1 adrenergic and antihistamine activity
7 Second generation antipsychotics Dopamine-serotonin antagonists Block D2 and 5HT2 receptors Affinity for 5HT2 receptors is higher than D2 receptors Clozapine was the first drug in this class Risperidone, olanzapine, quetiapine, paliperidone, iloperidone, asenapine, lurasidone, ziprasidone Some drugs in this class have fewer extrapyramidal symptoms More metabolic side effects
8 Receptor Binding Profile Risperidone High D2 activity Very high 5HT2 activity Moderate antihistamine and alpha 1 adrenergic activity Clinically insignificant muscarinic activity
9 Receptor Binding Profile Ziprasidone High D2 activity Very high 5HT2 activity Moderate alpha 1 adrenergic and antihistamine activity Clinical insignificant muscarinic activity
10 Receptor Binding Profiles Olanzapine High D2 activity Very high 5HT2 activity Very high antihistamine and muscarinic activity Moderate alpha 1 adrenergic activity
11 Receptor Binding Profiles Quetiapine Low D2 activity Low 5HT2 activity Very high antihistamine and alpha 1 adrenergic activity Moderate muscarinic activity
12 Third generation antipsychotics Dopamine partial agonists Aripiprazole Reduces dopaminergic neurotransmission through D2 partial agonism, not D2 antagonism
13 Antipsychotic Use in Canada FGAs mainly used for psychotic disorders SGAs approved for use in psychosis and bipolar disorder Some SGAs have been approved as adjunctive therapies for major depressive disorder with inadequate response to antidepressants Risperidone approved for use in the elderly with psychotic/aggressive behaviour in the setting of Alzheimer s Disease Black box warning SGAs used in children and youth with behavioural disorders (ADHD, Conduct Disorder) and autism Quetiapine Risperidone Aripiprazole Aripiprazole
14 Pharmacoepidemiology of Antipsychotic Use in Canada Use of antipsychotics has risen dramatically over the past 20 years in all ages groups Rise almost exclusively in SGAs Most common diagnoses associated with antipsychotic use 1. Mood disorders 2. Psychotic disorders 3. Anxiety disorders 4. Sleep disturbances
15 Risk of EPS with antipsychotics The development and promotion of SGA use was predicated on indications that SGAs would have a milder EPS profile than FGAs and therefore greater tolerability Comparative efficacy trials in schizophrenia suggest there is no advantage of SGAs over FGAs in effectiveness or tolerability SGAs and FGAs should be seen as lying on a multidimensional continuum rather than as two distinct classes; the tendency to group the drugs this way masks the complexity of side effects associated with individual drugs Very difficult to find adequate data that compares risk across all individual drugs
16 CATIE trial patients with schizophrenia in the US randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 months Primary aim was to delineate differences in overall effectiveness of these 5 treatments
17 CATIE trial 2005 No difference between the 5 drugs in prevalence of EPS Tardive dyskinesia Akathisia Drug-induced parkinsonism High rate of discontinuation across all 5 drugs (74%) More patients discontinued olanzapine due to metabolic side effects (9% vs 1-4% with other drugs); more patients discontinued perphenazine due to EPS (8% vs 2-4% with other drugs)
18 Risk of EPS with Antipsychotics Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia Multiple treatments meta-analysis of 212 clinical trials EPS measured as use of anti-parkinson drugs Leucht et al, Lancet 2013
19 Risk of Tardive Dyskinesia Correll 2008 Systematic review of studies of at least 1 year duration reporting the incidence of TD Compared SGAs (risperidone, olanzapine, quetiapine, clozapine and ziprasidone) as a group to FGAs (haloperidol and perphenazine)
20 Annual Tardive Dyskinesia Incidence Rates Children SGAs 0.35% (95% CI ) Adults SGAs 2.98% (95% CI ) FGAs 7.7% (95% CI ) Elderly SGAs 5.2% (95% CI ) FGAs 5.2% (95% CI )
21 Tardive dyskinesia prevalence rates SGAs 13.1% (95% CI ) FGAs 32.4% (95%CI )
22 Risk of Akathisia Miller 1997 Prospective study of 73 patients admitted to psychiatry and started on antipsychotics (mostly haloperidol and other FGAs) Calculated incidence rates for akathisia over a 4 week period 22.4% (95% CI ) All cases occurred within the first 2 weeks with a peak on day 3 Development of akathisia strongly associated with rapid dose escalation in the first days of treatment
23 Risk of Akathisia Meta-analysis of RCTs of new antipsychotic drugs for schizophrenia Prevalence of treatment emergent akathisia Medication Prevalence % (95%CI) I 2 Aripiprazole 8.5% ( ) I 2 0 Clozapine 7.9% ( ) I Olanzapine 8.7% ( ) I Paliperidone 3.3% ( ) I 2 0 Quetiapine 5.2% ( ) I 2 0 Risperidone 14.2% ( ) I Ziprasidone 8.3% ( ) I 2 1
24 Risk of Drug-Induced Parkinsonism Medication Prevalence % (95%CI) I 2 Aripiprazole 7.2% ( ) I 2 0 Asenapine 2.4% ( ) I 2 0 Clozapine 3.7% ( ) I 2 0 Olanzapine 8.1% ( ) I Quetiapine 8.8% ( ) I Risperidone 12.1% ( ) I Ziprasidone 10% ( ) I 2 0
25 Summary: Risk of EPS Clozapine and quetiapine appear to have a lower risk of EPS than other antipsychotics Haloperidol has a higher risk of EPS Risk is not zero for any of the antipsychotics Vigilance for EPS should be high in patients on any antipsychotic
26 Antipsychotic Induced Movement Disorders: Several Types Acute dystonia reactions Acute akathisia Parkinsonism Tardive dyskinesia Withdrawal dyskinesia Tardive dystonia Tardive akathisia
27 Neuroleptic Malignant Syndrome Rare adverse effect of antipsychotic medication Incidence % Onset occurs within hours to days after drug initiation Most occur within the first week; virtually all cases within 30 days
28 Neuroleptic Malignant Syndrome Hyperthermia (oral temperature >38C) Profuse diaphoresis Generalized rigidity Other abnormal movements can be present Changes in mental status delirium, stupor, coma Tachycardia, elevated blood pressure, tachypnea High CK
29 Neuroleptic Malignant Syndrome Once antipsychotic treatment is stopped, NMS is self-limited in most cases Mean recovery time after drug discontinuation is 7-10 days Most individuals recover within 1 week and nearly all by 30 days Fatality rates of 10-20% when not recognized early All dopamine antagonists have been associated with NMS High potency antipsychotics pose a greater risk than lowpotency agents and newer antipsychotics
30 Medication induced acute dystonia Seen within days of starting or increasing dose of antipsychotic, or after reducing the dosage of a medication used to treat extrapyramidal symptoms Dystonia= sustained muscle contractions causing twisting, repetitive movements and abnormal postures Cranial, neck and trunk muscles preferentially affected Retrocollis or torticollis Extension of trunk Deviation of eyes (oculogyric crisis) Forced jaw opening and tongue protrusion
31 Medication Induced Acute Akathisia Akathisia= state of excessive restlessness with a need to move Subjective complaints of inner tension and restlessness Observed excessive movements Shaking or rocking legs and trunk, pacing, marching in place, rubbing face, moaning to relieve discomfort, inability to sit or stand still Young children may not be able to articulate symptoms of akathisia May describe vague sensations of internal restlessness, discomfort, or anxiety; parents may state child appears anxious, more irritable/agitated Develops within a few weeks of starting or raising the dosage of a medication, or after reducing the dosage of a medication used to treat EPS
32 Neuroleptic induced parkinsonism Dose dependent adverse effect Develops within a few weeks of starting or raising the dosage of medication, or reducing the dosage of a medication for EPS Can be indistinguishable from idiopathic Parkinson s disease Classic resting tremor, rigidity, slowness of movement, shuffling gait, unilateral symptoms Fine, rhythmic perioral tremor may occur (rabbit syndrome) Can take months to resolve after withdrawal of offending agent
33 Neuroleptic Induced Tardive Dyskinesia Dyskinesia= abnormal movements Tardive dyskinesia refers to stereotypic, repetitive, choreiform movements of the mouth, lips and tongue, in a pattern that resembles chewing, sucking or lip pursing Occurs after using of a neuroleptic medication for at least a few months; can occur after a shorter period in the elderly Involvement of trunk, diaphragm, pelvis and distal limbs can occur Patients may be unaware of movements
34 Neuroleptic Induced Tardive Dyskinesia Movements of this type may appear after discontinuation, or after change or reduction in dosage of neuroleptic medication In these cases the condition is called neuroleptic withdrawal-emergent dyskinesia Withdrawal-emergent dyskinesia is usually time limited, lasting less than 4-8 weeks Dyskinesias persisting beyond this window is considered tardive dyskinesia
35 Neuroleptic induced tardive dystonia Subtype of tardive dyskinesia Sustained, slow, involuntary twisting movements affecting the limbs, trunk, neck or face Can be generalized, segmental or focal Common manifestations include retrocollis, facial grimacing, opisthotonic trunk extension, and hyperpronation of the arms Younger patients more likely to have generalized dystonia
36 Neuroleptic-induced tardive akathisia Persistent akathisia may occur as a subtype of tardive dyskinesia Defined as being present for at least one month when the patient is on a constant dose of a neuroleptic May occur in association with typical orolingual tardive dyskinesia or tardive dystonia Movements affecting the legs most common- marching in place while standing, while sitting crossing/uncrossing legs, rapidly abducting/adducting legs, pumping legs up and down
37 Neuroleptic-induced tardive akathisia Rocking of trunk while sitting Arm movements including smoothing hair with palms, rubbing face, folding/unfolding arms, repetitive rubbing anterior surface of the thighs Simple vocalizations such as grunting or moaning
38 Tardive dystonia and tardive akathisia Both of these movement disorders can persist for months to years, even after neuroleptic discontinuation or dosage reduction Can be very difficult to treat
39 Clinical Pearls When using an antipsychotic, try to use the lowest effective dose Medications should be gradually tapered when stopping Parkinsonism almost always begins with rigidity and cogwheeling- examine for these signs at every visit Acute dystonia is terrifying for patients Always counsel when first prescribing and advise to have benadryl on hand in case of an acute dystonic reaction
40 How do I examine for EPS?
Chapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationAntipsychotic Medication
Antipsychotic Medication Mary Knutson, RN 3-7-12 Mosby items and derived items 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 1 Clinical Uses of Antipsychotics Short-term: in severe depression and
More informationAntipsychotics. Neuroleptics/ Major Tranquilizers. Hiwa K. Saaed, PhD Pharmacology & Toxicology /5/18 1
Antipsychotics Neuroleptics/ Major Tranquilizers Hiwa K. Saaed, PhD Pharmacology & Toxicology hiwa.saaed@univsul.edu.iq 2018-2019 12/5/18 1 Learning objectives Pharmacy students should: be familiar with
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationWhat Team Members Other Than Prescribers Need To Know About Antipsychotics
What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
More informationCHAPTER 3. Schizophrenia and Antipsychotic Treatment
CHAPTER 3 Schizophrenia and Antipsychotic Treatment What is it? It is a severe, chronic, disabling brain disease Considered to have biological origins but exact unknown 1% of population affected Schizophrenia
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationANTIPSYCHOTICS/ NEUROLEPTICS
Pharmacological Interventions Tutorial Antipsychotic medications First Generation (Typicals) Includes phenothiazines, thioxanthenes, butyrophenones ANTIPSYCHOTICS/ NEUROLEPTICS Second Generation (Atypicals)
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationThe antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in
Antipsychotic Drugs The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in other psychotic and manic states.
More informationMethod. NeuRA Paliperidone August 2016
Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationChapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses
Chapter 17 Psychoses Drugs for Psychoses Delusions Hallucinations Illusions Paranoia Upper Saddle River, New Jersey 07458 All rights reserved. Classifications of Psychoses Acute episode Chronic episode
More informationAntipsychotic Use in the Elderly
Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationmovement disorders for psychiatrists
Movement disorders for psychiatrists Nandakumar Narayanan Assistant Professor, Neurology University of Iowa Thanks to Dr. Rodnitkzy Funding for my lab National Institutes of Health Carver Medical Trust
More informationSymbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)
Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination) Generic name: Olanzapine and fluoxetine combination Available strengths: 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg (Zyprexa/Prozac)
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationTHIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes
THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationAsenapine GENERAL INFORMATION DOSING INFORMATION. Available in generic
Asenapine Generic name Available brand Available strengths and formulations Available in generic Asenapine Saphris 5-mg and 10-mg sublingual tablets No GENERAL INFORMATION Asenapine (Saphris) is an antipsychotic
More informationData Collection Worksheets
Data Collection Worksheets PhenX Measure: Antipsychotic Medication Extrapyramidal Side Effects (#661600) PhenX Protocol: Antipsychotic Medication Extrapyramidal Side Effects (#661601) Date of Interview/Examination/Bioassay
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationAntipsychotics by Cayte Hoppner (updated by Glenice Bateman, Pharmacist, 2011)
Antipsychotics by Cayte Hoppner (updated by Glenice Bateman, Pharmacist, 2011) Introduction Antipsychotics are the foundation of pharmacological treatment of schizophrenia and other psychotic illnesses.
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More informationAssessing & Management of side effects: Part 1. medicationmanagement
Assessing & Management of side effects: Part 1 medicationmanagement What side effects of antipsychotic medication do you see in you clinical practice? How do you routinely assess for side effects of medication?
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Austedo) Reference Number: CP.PHAR.341 Effective Date: 06.13.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationMellaril (thioridazine)
Generic name: Thioridazine Available strengths: 10 mg, 25 mg, 50 mg, 100 mg, 200 mg tablets; 30 mg/ml, 100 mg/ml oral concentrate Available in generic: Yes Drug class: First-generation (conventional) antipsychotic
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationAntipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)
Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) CLeAR Webinar February 14, 2014 Paula Diaz (Pharm) Carol Ward MD Carol Ward Tertiary Mental Health IHA Hillside Centre (Acute Tertiary Mental
More informationOut with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine
More informationIs Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective
More informationHyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom
Hyperkinetic Movement Disorders Sarah Furtado, MD, PhD, FRCPC James case A mother brings her son James, 10, to your office because of repetitive sniffing sounds and repetitive eye blinking. This sniffing
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment
More informationLURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names
LURASIDONE THERAPEUTICS Brands LATUDA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn) Atypical antipsychotic (serotonin-dopamine
More informationANTIPSYCHOTICS AGENTS CONVENTIONAL
ANTIPSYCHOTICS AGENTS CONVENTIONAL Documentation A. FDA approved indications 1. Psychotic Disorder (Haloperidol, Thiothixene) 2. Schizophrenia 3. Bipolar Disorder, Manic (Chlorpromazine) 4. Severe Behavioral
More informationLatuda (lurasidone) Summary of the Risk Management Plan (RMP) for the Public
Latuda (lurasidone) Summary of the Risk Management Plan (RMP) for the Public An introduction to Risk Management Plans When a medicine is approved, the patient leaflet gives information about the side effects
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationSCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS
1 SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS OBJECTIVES 2 Know and understand: How to evaluate a person with psychotic symptoms The epidemiology and clinical characteristics of lateonset schizophrenia
More informationPERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes
PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,
More informationThe routine use of Intramuscular anticholinergics and depot antipsychotics BY DR. CHANTELLE MAGRI FOUNDATION YEAR 1
The routine use of Intramuscular anticholinergics and depot antipsychotics BY DR. CHANTELLE MAGRI FOUNDATION YEAR 1 Contributors Dr. Francesca Falzon Aquilina; BST psychiatry Dr Claire Axiaq; Resident
More informationANTIPSYCHOTIC POLYPHARMACY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University
More informationTRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names
TRIFLUOPERAZINE THERAPEUTICS Brands Stelazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Schizophrenia Bulletin vol. 36 no. 1 pp. 71 93, 2010 doi:10.1093/schbul/sbp116 Advance Access publication on December 2, 2009 The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations
More informationASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names
ASENAPINE THERAPEUTICS Brands SAPHRIS see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin, norepinephrine receptor antagonist (DSN-RAn) Atypical
More information2. OVERVIEW... 1 The Focus of These Guidelines... 1 These Guidelines: What is Not Covered... 2
TABLE OF CONTENTS 1. PURPOSE... 1 2. OVERVIEW... 1 The Focus of These Guidelines... 1 These Guidelines: What is Not Covered... 2 3. EVALUATION... 2 TABLE 1. Laboratory Studies for Evaluating Psychotic
More informationTreat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering
Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationUS Tardive Dyskinesia Market: Size, Trends & Forecasts ( ) December 2016
US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025) December 2016 US Tardive Dyskinesia Market Report Scope of the Report The report entitled US Tardive Dyskinesia Market: Size, Trends &
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationOptima Health. Schizophrenia. Next Review Date 9/19
Optima Health Schizophrenia Guideline History Original Approve Date 04/01 Review/Revise 3/05, 12/06, 09/08, 11/08, Dates 11/10, 7/11, 7/13, 7/15, 9/17 Next Review Date 9/19 These Guidelines are promulgated
More informationPromoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives
Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Mary Elizabeth Jones, Pharm BSc, RPh Senior Pharmacist AHCA Pharmacy
More informationMethod. NeuRA First versus second generation antipsychotics August 2016
Introduction First generation typical are an older class of antipsychotic than second generation atypical. First generation are used primarily to treat positive symptoms including the experiences of perceptual
More informationFebruary 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by
February 7-9, 2019 The Westin Fort Lauderdale Florida Provided by Addressing Your Greatest Concerns in Schizophrenia Management: From Suicide to Relapse Prevention and the Role of LAIs John Lauriello,
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationHow did we get here? 1876 Methylene Blue. Insecticide 1935 Du Pont Anthelmintic. Garrett McCann, RPh
Polypharmacy, Adverse Effects, and the Importance of Tapering Medications for People with Intellectual and Developmental Disabilities Garrett McCann, RPh How did we get here? 1876 Methylene Blue Insecticide
More informationPERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes
PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, antiemetic) Commonly Prescribed
More informationObjectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency
More informationFirst Episode Schizophrenia
First Episode Schizophrenia Abigail Donovan, M.D. Assistant Professor of Psychiatry, Harvard Medical School Director, First Episode and Early Psychosis Program MGH Schizophrenia Program Massachusetts General
More informationMedication Management in Tic Disorders. Erica Greenberg, MD Pediatric Psychiatry OCD and Tic Disorders Program 7/29/18
Medication Management in Tic Disorders Erica Greenberg, MD Pediatric Psychiatry OCD and Tic Disorders Program 7/29/18 Speaker Disclosures: No relevant disclosures (Clinical research study funded in part
More information1 Chapter 1 A Review on Antipsychotic Drug Substances and. Importance of Alternate Synthetic Approaches to Drug Substances
CHAPTER-1: 1 A Review on Antipsychotic Drug Substances and Importance of Alternate Synthetic Approaches to Drug Substances for Pharmaceutical Industry: PART-1: Review on Antipsychotic Drug Substances 1.1.1:
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationAntipsychotic Drugs. Munir Gharaibeh, MD, PhD, MHPE March, 2018
Antipsychotic Drugs Munir Gharaibeh, MD, PhD, MHPE March, 2018 المھدي ات( م ض ا د ا ت( Antipsychotic Drugs These are the drugs used in the treatment of psychotic diseases( e.g. schizophrenia). ا ل ك ب
More informationMovement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial
Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial Stanley N. Caroff, MD a,b, *, Irene Hurford, MD a,b, Janice Lybrand, MD a, E. Cabrina Campbell, MD a,b KEYWORDS
More informationAPPROACH TO PSYCHOSIS IN PRIMARY CARE
APPROACH TO PSYCHOSIS IN PRIMARY CARE Family Medicine Forum 2015 Annual Meeting Toronto, Ontario November 12-14, 2015 Jon Davine, MD, CCFP, FRCP(C) Associate Professor, McMaster University Objectives
More informationCHLORPROMAZINE. THERAPEUTICS Brands Thorazine see index for additional brand names
CHLORPROMAZINE THERAPEUTICS Brands Thorazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS-RAn) Conventional antipsychotic
More informationBehavioural and Psychological Symptoms and Medications Presentation
1 2 Vover s research indicated that antipsychotic med are frequently used for individual presenting with disruptive behaviours. This often combined with physical restraints Efficacy of use not justify
More informationPATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE
SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each
More informationCharles P. Samenow, MD, MPH Department of Psychiatry George Washington University
Charles P. Samenow, MD, MPH Department of Psychiatry George Washington University Objectives Identify the epidemiology, symptomatology, course, causality (including genetic risk) and treatment options
More informationFirst-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
1 First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness This continuing education monograph examines the results of a comparative effectiveness review to compare
More informationMedical Manual. Modified by Cassis Henry, M.D. and Scott Stroup, M.D. RAISE Connection Psychopharmacology Manual. Robert Buchanan, M.D.
Medical Manual Modified by Cassis Henry, M.D. and Scott Stroup, M.D. RAISE Connection Psychopharmacology Manual Robert Buchanan, M.D. Julie Kreyenbuhl, PharmD., PhD Table of Contents I. General Principles
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationSchizophrenia. Psychology 372 Physiological Psychology. Overview. Characterized by. Disorganized Thoughts Hallucinations Delusions Bizarre behaviors
Overview Schizophrenia Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Probably consists of more than one disorder Is the most devastating
More informationSchizophrenia. Introduction. Overview and Facts
Introduction is a chronic, severe and disabling brain disease that typically shows its first clear symptoms in late adolescence or early adulthood. It is one of several types of Psychotic Disorders. It
More informationRiding the Waves: Tools for the Management of Bipolar Disorder
Riding the Waves: Tools for the Management of Bipolar Disorder Jacintha S. Cauffield, Pharm.D., BCPS, CDE Associate Professor of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School
More informationOlanzapine/Fluoxetine
Olanzapine/Fluoxetine Generic names Available brand Available strengths and formulations (olanzapine/fluoxetine) Available in generic Olanzapine and fluoxetine combination Symbyax 3-mg/25-mg, 6-mg/25-mg,
More informationSlide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts
Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationTardive Dyskinesia New approaches in diagnosis and treatment
Tardive Dyskinesia New approaches in diagnosis and treatment Steven T. Szabo, MD, PhD Psychiatry and Behavioral Sciences Division of Translational Neuroscience Duke University Medical Center Durham, NC
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationDrugs used in schizophrenia قادة فریق علم الا دویة : الشكر موصول لا عضاء الفریق المتمیزین :
MCQs SAQs Summar y Drugs used in schizophrenia قادة فریق علم الا دویة : لین التمیمي & عبدالرحمن ذكري الشكر موصول لا عضاء الفریق المتمیزین : روان سعد القحطاني فؤاد بھجت عبدالرحمن العریفي حاتم النداح pharma436@outlook.com
More informationREGLAN IS A DANGEROUS PSYCHIATRIC DRUG: THE FACTS YOU NEED TO KNOW
1 of 6 REGLAN IS A DANGEROUS PSYCHIATRIC DRUG: THE FACTS YOU NEED TO KNOW Article Researched and Written by Dr. Josh Ferguson 2018 The drug Metoclopramide also known primarily by its brand name Reglan,
More informationThis factsheet covers:
Antipsychotics If you experience psychosis as part of your illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More informationThe alternate reality of schizophrenia
The alternate reality of schizophrenia MICHAEL TRINSEY SCHIZOPHRENIA IS A GROUP of chronic, disabling psychiatric disorders characterized by disturbed thinking and disorganized speech. Patients with schizophrenia
More informationAntipsychotics. This factsheet covers -
Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationElements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what
More informationAbnormal Involuntary Movement Scale (AIMS)
Abnormal Involuntary Movement Scale (AIMS) Please visit us at www.lundbeck.com/cnsforum Examination Procedure Either before or after completing the examination procedure, observe the patient unobtrusively
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More information